Clinical trial of montelukast tablets combined with Yupingfeng grannies in the treatment of allergic purpura
10.13699/j.cnki.1001-6821.2017.17.010
- VernacularTitle:孟鲁司特片联合玉屏风颗粒治疗过敏性紫癜的临床研究
- Author:
Ai-Hua JI
1
;
Zhen-Ju PENG
Author Information
1. 济南市儿童医院皮肤科
- Keywords:
montelukast tablet;
Yupingfeng granule;
allergic purpura;
safety
- From:
The Chinese Journal of Clinical Pharmacology
2017;33(17):1644-1646
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical efficacy and safety of montelukast tablets combined with Yupingfeng granules in the treatment of allergic purpura.Methods A total of 130 children with allergic purpura were randomly divided into control group and treatment group with 65 cases per group.Control group was treated with montelukast,4 mg · d-1 for 3-4 years old,5 mg· d-1 for ＞ 6 years old,every night,oral.Treatment group was given Yupingfeng granules,2.5 g each time for 3-7 years old,5 g each time for 7-14 years old,tid,oral,on the basis of the control group.Two groups were treated for 3 months.The clinical efficacy,recurrence rate and adverse drug reactions were compared between two groups.Results After treatment,the total effective rates in treatment and control groups were 93.84％ (61/65 cases) and 75.38％ (49/65 cases),the recurrence rates in treatment and control groups were 0 (0/65 cases) and 15.38％ (10/65 cases),the differences were statistically significant (all P ＜ 0.05).The adverse drug reactions in treatment group were dizziness,diarrhea and fever,which in control group were fever,nausea,dizziness and chest tightness.The incidences of adverse drug reactions in treatment and control groups were 6.15％ and 7.69％ without significant difference (P ＞ 0.05).Conclusion Montelukast tablets combined with Yupingfeng granules have a definitive clinical efficacy in the treatment of allergic purpura,without increasing the incidence of adverse drug reactions.
